About Taste receptor type 2 member 46
Taste receptor type 2 member 46 (TAS2R46) is a protein
from Homo sapiens identified by UniProt accession
P59540, 309 residues long.
MolForge cross-references it against 0 known binders and
17 disease associations.
Target properties
| Protein name | Taste receptor type 2 member 46 |
|---|
| UniProt accession | P59540 |
|---|
| Gene | TAS2R46 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 309 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (3)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (17)
Diseases linked to this target (Open Targets).
- ovarian cancer · score 0.18
- lung adenocarcinoma · score 0.18
- thyroid gland adenocarcinoma · score 0.16
- head and neck squamous cell carcinoma · score 0.13
- sensory perception of bitter taste · score 0.06
- sebaceous of Jadassohn nevus · score 0.05
- blood protein measurement · score 0.05
- breast carcinoma · score 0.03
- cancer · score 0.00
- ulcerative colitis · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P59540-F1 | alphafold | PREDICTED | 86.08 | — |
Amino-acid sequence (309 residues)
MITFLPIIFS ILIVVTFVIG NFANGFIALV NSIEWFKRQK ISFADQILTA LAVSRVGLLW VLVLNWYATE LNPAFNSIEV RITAYNVWAV INHFSNWLAT SLSIFYLLKI ANFSNLIFLH LKRRVKSVVL VILLGPLLFL VCHLFVINMN QIIWTKEYEG NMTWKIKLRS AMYLSNTTVT ILANLVPFTL TLISFLLLIC SLCKHLKKMQ LHGKGSQDPS MKVHIKALQT VTSFLLLCAI YFLSIIMSVW SFESLENKPV FMFCEAIAFS YPSTHPFILI WGNKKLKQTF LSVLWHVRYW VKGEKPSSS
Explore Taste receptor type 2 member 46 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets